BioCentury
ARTICLE | Clinical News

AC480: Phase I started

January 3, 2011 8:00 AM UTC

Ambit began an open-label, dose-escalation Phase I trial to evaluate IV AC480 given on the first 2 days of a 21-day cycle with or without Taxotere docetaxel in 100 patients. Ambit licensed AC480 from...